Feasibility of the Engager™ aortic transcatheter valve system using a flexible over-the-wire design

Simon H. Sündermann*, Jürg Grünenfelder†, Roberto Corti‡, Ardawan J. Rastan§, Axel Linke¶, Rüdiger Lange®, Volkmar Falk* and Sabine Bleiziffer*

* Division of Cardiac and Vascular Surgery, University Hospital Zurich, Zurich, Switzerland
† Division of Cardiology, University Hospital Zurich, Zurich, Switzerland
‡ Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
§ Department of Cardiology, Heart Center Leipzig, Leipzig, Germany
¶ Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
® Department of Cardiovascular Surgery, German Heart Centre Munich, Munich, Germany

* Corresponding author. Division of Cardiac and Vascular Surgery, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. Tel: +41-442554775; fax: +41-442554446; e-mail: simon.suendermann@usz.ch (S.H. Sündermann).

Received 26 March 2012; received in revised form 16 May 2012; accepted 24 May 2012

Abstract

OBJECTIVES: The aim was to investigate the safety and feasibility of the redesigned Engager™ transcatheter aortic valve implantation (TAVI) system.

METHODS: Transapical aortic valve implantation with the Engager™ valve prosthesis was intended in 11 patients, and performed in 10. Endpoints were defined according to the valve academic research consortium recommendations for reporting outcomes of TAVI in clinical trials.

RESULTS: All 10 patients were implanted successfully. No device-related or delivery system complications like coronary obstruction or aortic dissection emerged. One patient (10%) died from non-device-related reasons at post-operative day 23 of multi-organ failure. The invasively measured peak-to-peak gradient after valve implantation was 7.1 ± 3.5 mmHg. In 90%, there was no or only trivial (sgrad I) aortic regurgitation due to paravalvular leakage. In 10% of the patients, aortic regurgitation grade I–II was observed. At 30-day follow up, the mean gradient was 15.6 ± 4.9 mmHg, and no more than a mild transvalvular and paravalvular aortic regurgitation was seen as assessed by transthoracic echocardiography.

CONCLUSIONS: Application of the Engager™ TAVI system is safe and feasible. Prosthesis deployment in an anatomically correct position was facilitated by the design of the valve prosthesis and was successful in all patients. No device or delivery-system-related complications emerged. Safety and feasibility endpoints were met. Good results concerning the aortic valve performance after implantation and at 30-day follow up were ascertained. These results encouraged the start of a European Pivotal trial including patients to date.

Keywords: Transapical aortic valve replacement • Minimally invasive surgery • Aortic valve disease

INTRODUCTION

Several prostheses for transcatheter aortic valve implantation (TAVI) have been developed [1–5]. A multicentre study with the first generation of the Medtronic Engager™ Aortic Valve (formerly called Ventor Embracer) prosthesis established the feasibility of implantation into the correct anatomical position of this self-expandable valve. However, following aortic dissections in 4 out of 30 patients caused by non-covered commissural posts and a rigid straight delivery catheter, a redesign of the delivery system was completed [6]. A key feature of the redesigned system is a flexible soft-tip over-the-wire delivery-catheter that covers the entire prosthesis up to the stage of deployment. Here, we describe the 30-day results of the feasibility study with the new Engager™ TAVI system.

METHODS

Approval by competent authorities as well as the local ethical committees in three European centres was obtained for a multicentre feasibility study in elderly patients (≥75 years of age) with severe (mean gradient >40 mmHg, jet velocity >4.0 m/s, valve area ≤0.8 cm² or indexed valve area ≤0.5 cm²/m²) symptomatic aortic stenosis who were considered to be at high risk (logistic EuroSCORE ≥15%) for surgical aortic valve replacement. All patients gave written informed consent. The endpoints were defined according to the valve academic research consortium recommendations for reporting outcomes of TAVI in clinical trials [7].

The valve

The Engager™ Aortic Valve bioprosthesis (Medtronic, Inc., Minneapolis, MN, USA), shown in Fig. 1, is a biological heart valve prosthesis composed of three leaflets, cut from tissue-fixed bovine pericardium, sewn to a polyester sleeve and mounted on a compressible and self-expanding Nitinol frame. The stent assembly consists of a shaped main frame and a support frame, which are coupled together so as to form the commissural posts of the valve. Two types of sewing materials are
used: polyester and expanded polytetrafluoroethylene. For this study, the bioprosthesis was available in two sizes, labelled as 23 and 26 according to the diameter at the commissural outlet (in mm); the Engager 23 and 26 have a total deployed frame length of 25.5, and 27.5 mm, respectively. These two sizes are designed to fit an effective aortic annulus diameter by computed tomography (CT) between 21 and 26.5 mm, typically corresponding to an echocardiographic annulus diameter between 19 and 26. The valve is sterilized and stored in a glutaraldehyde solution. To achieve an anatomically correct position, a defined height of implantation and to minimize the risk of coronary obstruction, the side arms fixed at the main frame of the prosthesis are designed to be placed into the sinuses of the aortic root.

Implant procedure

The procedures were performed from September 2010 to July 2011. All procedures were performed in a surgical hybrid suite and with cardiopulmonary bypass on stand-by. The delivery system is composed of a 29Fr (inner diameter) introducer and a flexible delivery catheter with a 13Fr shaft, which form one integral unit (Fig. 2). Prior to the procedure, the valve was crimped and mounted onto the delivery system and handed pre-flashed to the operator. A temporary trans-venous pacemaker wire was inserted for rapid pacing. A 6Fr femoral arterial sheath was inserted into one femoral artery and a pigtail catheter was placed into the aortic root for contrast aortography. A 6F introducer sheath was inserted into one femoral vein and a guidewire placed in the right atrium to establish access for fast cannulation in case conversion to extracorporeal circulation became necessary (safety precaution). Low-dose heparin was given with a target activated clotting time of 250 s.

A standard transapical approach was applied. After exposure of the apex, pledgeted purse string sutures were placed. The left ventricular apex was punctured with an 18G Seldinger-type needle and a 6Fr soft sheath was inserted. A standard soft guidewire was advanced across the aortic arch into the descending aorta with the help of a right coronary Judkins or Amplatz catheter and exchanged for a 0.0035 super-stiff guidewire. The 6Fr sheath was exchanged for a 14Fr sheath and a balloon valvuloplasty catheter, selected according to the annulus diameter, was positioned and balloon valvuloplasty was performed during a brief period of rapid ventricular pacing. The delivery system with the mounted Engager valve was then inserted over the guidewire and with the introducer held fixed at the desired depth, the delivery catheter was advanced across the aortic valve under fluoroscopic guidance. Commissural alignment was performed using the technique of rotational positioning under fluoroscopic control (Fig. 3). The Engager support arms were then gradually exposed by controlling a blue rotating knob at the handle. The support arms were then positioned in the aortic sinuses by withdrawing the delivery catheter under fluoroscopic and tactile control. Before deployment, correct sub-coronary positioning was verified by aortic root angiography. Repositioning (if necessary with recapture of the support arms) could be performed at this stage. After verifying that the desired deployment position was achieved, a safety-button was unlocked, allowing the uncovering of the commissural posts by further rotating the blue knob. Self-expandable deployment was controlled by rotating a second (black) knob at the handle while holding the support arms engaged against the valve. This was performed under rapid ventricular pacing in seven patients and without pacing in three. With the last turn of the knob, the device was released. The delivery system was reconnected with the introducer tube and the whole system including the guide wire, was removed and the apex was closed with the purse string sutures. Valve position and function were immediately assessed using angiographical and echocardiographical imaging as well as by simultaneous recording of the left ventricular and aortic pressure curves. The pericardium was partially closed over the apex and a left lateral chest tube inserted. Intercostal blockade was performed using a local anaesthetic. The intercostal incision was closed in a standard fashion. Femoral sheaths were removed. Post-operative device-specific medical therapy consisted of aspirin 100 mg daily indefinitely and clopidogrel 75 mg daily for at least 3 months.
RESULTS

Patient baseline characteristics

Eleven patients were brought to the operating room (OR) with the intention to treat, and 10 patients underwent the implantation procedure, all of them successfully. The patient flowchart is summarized in Fig. 4: the baseline characteristics of the 11 patients brought to the OR are summarized in Table 1. Mean age was $82.5 \pm 3.6$ years (range from 76 to 88 years). Nine were female. The majority of patients were in New York Heart Classification class III (eight patients) or IV (two patients) and one patient had undergone previous cardiac surgery. Mean logistic EuroSCORE was $24.6 \pm 13.6\%$ (range from 14.9 to 52.5%). Mean aortic annulus diameter as assessed by transoesophageal echocardiography was $21.0 \pm 0.8$ mm. Aortic annulus perimeter and derived effective mean diameter by CT were $74 \pm 2.3$ and $23.6 \pm 0.7$ mm, respectively. Mean aortic valve pressure gradient was $49.3 \pm 13.5$ mmHg assessed by continuous-wave doppler.

Procedural details

Procedural details and outcomes are summarized in Table 2. Accurate valve placement was achieved in all 10 implanted patients. Mean fluoroscopy time was $8.6 \pm 2.5$ min; $103 \pm 32$ ml of contrast medium was used per procedure. Skin-to-skin time was $94.5 \pm 16.7$ min. No device related or delivery-system-related complications occurred in any of the 10 implanted patients.

Safety and efficacy

Death within 30 days post-implant occurred in 2 of 11 patients (18%) brought to the OR and 1 of the 10 patients (10%) in whom the valve implantation was attempted.

One patient (logistic EuroSCORE 16.6%) experienced hypotension and cardiac arrest during insertion of the guidewire through the apex to the aortic arch. The patient was stabilized through the use of extracorporeal membrane oxygenation and balloon valvuloplasty was performed. The procedure was aborted without implantation of any prosthetic valve because the patient deteriorated again and expired after a second attempt at resuscitation.
The second patient (logistic EuroSCORE 48.9%) became haemodynamically unstable upon introduction of the balloon valvuloplasty sheath, and experienced cardiac arrest. The patient was resuscitated and the Engager™ valve bioprosthesis was successfully deployed. The patient was transferred to the ICU in a stable condition, but had a complicated post-operative course (including respiratory insufficiency requiring reintubation, tracheal perforation, third degree atrioventricular (AV) block requiring pacemaker implantation, renal insufficiency requiring dialysis and bowel ischaemia requiring resection), and ultimately died on post-implant day 23 of multi-organ failure. There were no strokes or myocardial infarctions during the first 30 days after implantation. One patient (10%) with chronic renal insufficiency required dialysis in the early post-operative period.

Prosthetic valve performance

The invasively measured peak-to-peak gradient after valve implantation was 7.1 ± 3.5 mmHg. In nine of the implanted patients, there was no or only trivial (grad I or less) aortic regurgitation due to paravalvular leak. In one patient, aortic regurgitation grade I–II was observed. There were no cases of aortic insufficiency greater than grade II. At 30-day follow up, average mean aortic gradient was 15.6 ± 4.9 mmHg (one patient who may have benefited from a post-dilatation had a mean gradient of 24 mmHg; all other values ranged between range 8.0 and 17 mmHg). No more than mild transvalvular and paravalvular aortic regurgitation was assessed by transthoracic echocardiography (Table 3).

Prosthetic valve-associated complications

Two of 10 implanted patients (20%) required permanent pacemaker implantation for complete atrioventricular block. One patient developed complete atrioventricular block for a short period of time followed by resuscitation, and during the following day appeared to have stable sinus rhythm with AV-block grade I. One patient with known episodes of atrial fibrillation pre-implantation developed atrial fibrillation requiring electrocardioversion at Day 5. No coronary obstructions or aortic dissections occurred, no undesired mitral interference, or any other prosthesis-related adverse events were observed and none of the implanted prostheses was explanted.

DISCUSSION

The purpose of this feasibility study was to assess the safety and clinical performance of the re-designed Engager™ TAVI system prior to commencing a multicentre pivotal study. Ten of 11 patients who were considered high risk for conventional aortic valve replacement have been successfully implanted through a
transapical approach with the Medtronic Engager™ bioprosthesis using the new delivery system. One patient died in the OR before valve implantation was attempted and 1 of the 10 implanted patients died on post-procedure day 23 after experiencing multiple serious adverse events resulting in an as-treated mortality rate of 10%. The flexible over-the-wire delivery system adapted well to the aortic anatomy, and allowed for safe and quick implantation without evidence of aortic injury or any other delivery-system-related complications. No patient experienced a stroke after implantation and until 30 days of follow up. No vascular complication occurred in our patient population. These results confirm the findings of other trials reporting a low incidence of major vascular complications [8, 9] for the transapical approach. Although the number of patients in this feasibility study is small, the current results suggest that the redesign of the delivery system, as a flexible, fully covered over-the-wire system, has effectively corrected the root cause of the aortic dissections observed in the first-in-man study.

At the end of the procedure, 9 of 10 patients had no more than grade I perivalvular regurgitation, and none had grade II or more. No patient was documented with more than mild transvalvular or paravalvular regurgitation by colour flow Doppler echocardiography at 30-day follow-up. Different values for the mean transprosthetic gradients were obtained with two different methods and under different haemodynamic conditions: the peak-to-peak pressure gradient during general anaesthesia and the transthoracic echocardiographically measured gradient based on flow velocity and calculated with the modified Bernoulli equation. The geometry of the support arms facilitates predictable deployment of the prosthesis into an anatomical correct positioning with a defined height of implantation, making the procedure both intuitive and reliable. Adverse events like valve dislocation and coronary obstruction as described for other prostheses [8] can potentially be avoided by the design, and were indeed not observed. The incidence and type of reported serious adverse events could be primarily attributed to the study’s patient population with a mean logistic EuroSCORE of 24.5%.

In conclusion, the current results of the Engager™ feasibility study demonstrated the successful deployment of the Engager™ bioprosthesis into an anatomically correct position without perioperative delivery system-related complications using the redesigned Engager™ transapical catheter delivery system. As a result, patients are currently being enrolled into the multinational prospective pivotal study, in order to confirm the safety and clinical performance of the Engager™ bioprosthesis in a larger patient population.

ACKNOWLEDGEMENTS

We thank Ehud Schwammenthal for his invaluable work as proctor of the Engager™ TAVI system. As a co-founder of Ventor technologies Ltd that primarily introduced the valve, he participated in all procedures and gave indispensable input during the implantations and significantly participated in completing this manuscript.

Conflict of interest: none declared.

REFERENCES